加载中
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
前收盘价
US$1.16
+US$0.13 · +12.62%
盘后
US$1.15
−US$0.01 · -0.86%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
日内区间
当前US$1.16
52周区间
当前US$1.16
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
56
多空交织
风险
66
高风险
动量
16
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
日内区间
当前US$1.16
52周区间
当前US$1.16
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 981.3万 USD | 949.9万 USD | 470.4万 USD | 196.7万 USD | 181万 USD |
| 销售、一般及管理费用 | 627.7万 USD | 504.8万 USD | 239.7万 USD | 245.4万 USD | 212万 USD |
| 营业费用 | 1609万 USD | 1454.7万 USD | 710.4万 USD | 443.2万 USD | 404万 USD |
| 利息收入 | — | 6.2万 USD | 7000 USD | 1.1万 USD | 2.6万 USD |
| 利息支出 | — | 62.8万 USD | — | 3000 USD | — |
| 折旧和摊销 | 4.2万 USD | 3.6万 USD | 1.3万 USD | 2.3万 USD | 4.2万 USD |
| 营业利润 | −1609万 USD | −1454.7万 USD | −710.4万 USD | −443.2万 USD | −404万 USD |
| 净利润 | −1938.8万 USD | −2259.7万 USD | −709.7万 USD | −443.5万 USD | −406.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
